Endothelial epas1 deficiency is sufficient to promote parietal epithelial cell activation and fsgs in experimental hypertension

Yosu Luque, Olivia Lenoir, Philippe Bonnin, Lise Hardy, Anna Chipont, Sandrine Placier, Sophie Vandermeersch, Yi Chun Xu-Dubois, Blaise Robin, Héléne Lazareth, Michéle Souyri, Léa Guyonnet, Véronique Baudrie, Eric Camerer, Eric Rondeau, Laurent Mesnard, Pierre Louis Tharaux*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

18 Citations (Scopus)


FSGS, the most common primary glomerular disorder causing ESRD, is a complex disease that is only partially understood. Progressive sclerosis is a hallmark of FSGS, and genetic tracing studies have shown that parietal epithelial cells participate in the formation of sclerotic lesions. The loss of podocytes triggers a focal activation of parietal epithelial cells, which subsequently formcellular adhesions with the capillary tuft. However, in the absence of intrinsic podocyte alterations, the origin of the pathogenic signal that triggers parietal epithelial cell recruitment remains elusive. In this study, investigation of the roleof the endothelial PASdomain-containingprotein 1 (EPAS1), a regulatorya subunit of the hypoxia-inducible factor complex, during angiotensin II-induced hypertensive nephropathy provided novel insights intoFSGSpathogenesis in the absenceof a primarypodocyte abnormality.We infused angiotensin II into endothelial-selective Epas1 knockout mice and their littermate controls. Although the groups presented with identical high BP, endothelial-specific Epas1 gene deletion accentuated albuminuria with severe podocytelesions andrecruitment of pathogenic parietalglomerularepithelial cells.These lesions anddysfunctionof the glomerular filtration barrier were associated with FSGS in endothelial Epas1-deficient mice only. These results indicate that endothelial EPAS1 has a global protective role during glomerular hypertensive injuries without influencing the hypertensive effect of angiotensin II. Furthermore, these findings provide proof of principle that endothelial-derived signaling can trigger FSGS and illustrate the potential importance of the EPAS1 endothelial transcription factor in secondary FSGS.

Original languageEnglish
Pages (from-to)3563-3578
Number of pages16
JournalJournal of the American Society of Nephrology
Issue number12
Publication statusPublished - Dec 2017


Dive into the research topics of 'Endothelial epas1 deficiency is sufficient to promote parietal epithelial cell activation and fsgs in experimental hypertension'. Together they form a unique fingerprint.

Cite this